Second Irregularity In NSABP Data Found; Fisher Takes Leave As Group’s Chairman
In Brief: Ross Retires From Bristol-Myers, Forms Own Consulting Service; Obey Wins Key Post
NCI Promises Strong Monitoring Process Visco Calls For Independent Review; Rep. Dingell Plans Hearing April 13
Biotech Organization Endorses Measures On Orphan Drug Act
Salick Signs contract for Fixed-Price Oncology Services
DCE Advisors OK RFAs In Occupational Cancer, H. Pylori
Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives









